Search Results Search Sort by RelevanceMost Recent Medicine and Society Jul 2019 Who Are “Unrepresented” Patients and What Count as “Important” Medical Decisions for Them? David Ozar, PhD A look at current literature and work by a statewide initiative can motivate development of policies that help respond to unrepresented patients’ needs. AMA J Ethics. 2019;21(7):E611-616. doi: 10.1001/amajethics.2019.611. Medicine and Society Jul 2019 Who Should Make Decisions for Unrepresented Patients Who Are Incarcerated? Matthew Tobey, MD, MPH and Lisa Simon, DMD Decisions for patients who are unrepresented and incarcerated could be made by different classes of possible decision makers “inside” and “outside.” AMA J Ethics. 2019;21(7):E617-624. doi: 10.1001/amajethics.2019.617. Medicine and Society Sep 2024 How Should Treatment of Animals Beyond the Lab Factor Into Institutional Review? Laurie Sellars, MA and Jeff Sebo, PhD Humans make critical decisions about nonhuman lab animals outside the lab: during breeding, transportation, and end-of-study protocols. AMA J Ethics. 2024;26(9):E716-723. doi: 10.1001/amajethics.2024.716. Medicine and Society Sep 2024 How Should the 3 R’s Be Revised and Why? Rebecca Critser, JD, LLM, MA and Paul Locke, JD, DrPH How to amend the 3 R’s has been driven mainly by philosophical ethics approaches to nonhuman animal rights and by scientific advancement. AMA J Ethics. 2024;26(9):E724-729. doi: 10.1001/amajethics.2024.724. Medicine and Society Nov 2024 How Should We Expand Access to Psychedelics While Maintaining an Environment of Peace and Safety? Zachary Verne and Jeffrey Zabinski, MD, MSW, MA This article examines widespread adoption of ketamine as a proxy for psychedelics. AMA J Ethics. 2024;26(11):E868-874. doi: 10.1001/amajethics.2024.868. Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777.
Medicine and Society Jul 2019 Who Are “Unrepresented” Patients and What Count as “Important” Medical Decisions for Them? David Ozar, PhD A look at current literature and work by a statewide initiative can motivate development of policies that help respond to unrepresented patients’ needs. AMA J Ethics. 2019;21(7):E611-616. doi: 10.1001/amajethics.2019.611.
Medicine and Society Jul 2019 Who Should Make Decisions for Unrepresented Patients Who Are Incarcerated? Matthew Tobey, MD, MPH and Lisa Simon, DMD Decisions for patients who are unrepresented and incarcerated could be made by different classes of possible decision makers “inside” and “outside.” AMA J Ethics. 2019;21(7):E617-624. doi: 10.1001/amajethics.2019.617.
Medicine and Society Sep 2024 How Should Treatment of Animals Beyond the Lab Factor Into Institutional Review? Laurie Sellars, MA and Jeff Sebo, PhD Humans make critical decisions about nonhuman lab animals outside the lab: during breeding, transportation, and end-of-study protocols. AMA J Ethics. 2024;26(9):E716-723. doi: 10.1001/amajethics.2024.716.
Medicine and Society Sep 2024 How Should the 3 R’s Be Revised and Why? Rebecca Critser, JD, LLM, MA and Paul Locke, JD, DrPH How to amend the 3 R’s has been driven mainly by philosophical ethics approaches to nonhuman animal rights and by scientific advancement. AMA J Ethics. 2024;26(9):E724-729. doi: 10.1001/amajethics.2024.724.
Medicine and Society Nov 2024 How Should We Expand Access to Psychedelics While Maintaining an Environment of Peace and Safety? Zachary Verne and Jeffrey Zabinski, MD, MSW, MA This article examines widespread adoption of ketamine as a proxy for psychedelics. AMA J Ethics. 2024;26(11):E868-874. doi: 10.1001/amajethics.2024.868.
Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777.
